Compare QBTS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QBTS | XBIT |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | 388 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 66.8M |
| IPO Year | 2022 | 2015 |
| Metric | QBTS | XBIT |
|---|---|---|
| Price | $16.54 | $2.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $34.65 | N/A |
| AVG Volume (30 Days) | ★ 13.3M | 36.5K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $72.74 | N/A |
| Revenue Next Year | $89.80 | $30.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.75 | $2.09 |
| 52 Week High | $46.75 | $3.44 |
| Indicator | QBTS | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 47.52 |
| Support Level | $12.75 | $2.16 |
| Resistance Level | $19.01 | $2.48 |
| Average True Range (ATR) | 0.88 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 18.95 | 66.67 |
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.